The World Health Organization (WHO) introduced the concept of essential medicines in 1977. Essential medicines are intended to be available within the context of functioning health systems at all times in adequate amounts, in the appropriate dosage forms, with assured quality, and at a price the individual and the community can afford. They are selected with due regard to public health relevance, evidence of efficacy and safety, and comparative cost-effectiveness. In Africa, many countries have adopted the Essential Medicines List concept and embraced the principles of rational use of medicines. However there are critical challenges which this 2 day conference and exposition will seek to address. The areas of focus of PharmaConnect Africa (PharmaConnect-A 2017) will be local pharmaceutical manufacturing, offshore procurement and distribution, and the over-arching role of medicine regulation along the whole value chain. Discussions will cut across both human and animal health care in Africa.
PharmaConnect-A 2017 will bring together all strategic stakeholders from key regulatory authorities, local and transnational companies, academics and NGOs for discussions around their roles and responsibilities in affordable and efficient health care delivery in Africa with a specific focus on Essential Medicines.
Scientific Review Committee (SRC)
Prof David R Katerere [PhD] – Tshwane University of Technology – SRC Chair
Has 21 years post-qualification experience including stints at Farmovs-Parexel CRO Pty Ltd and the South African Medical Research Council (SAMRC). He was also a visiting scientist at Scynexis Inc, RTP, North Carolina in 2010. His areas of interest and expertise are natural products / pharmacognosy, analytical chemistry and regulatory science. He is on the expert committees of Medicines Control Council, was an expert advisor / trainer on scientific matters to the SAMRC and has completed several consulting assignments for Department of Trade and Industry as well as United Nations Industrial Development Organization (UNIDO).
Robyn Daniel [B Pharm | FPS] – MRA Regulatory Consultants
Is a pharmacist with over 20 years industry experience mainly in the regulatory field including 9 years as a Responsible Pharmacist for a UK based pharmaceutical company . She is a director and partner in MRA Regulatory Consultants based in Pretoria and is involved in submission and maintenance of dossiers in 24 Sub-Saharan Africa. She has been involved in ZAZIBONA joint review pilot projects as well as WHO harmonised pilot project. Robyn is a member of National Association of Pharmaceutical Manufacturers (NAPM) and the vice chair of the ITG (Industry Task Group).
Dr Judy Coates [PhD] – Innovative Pharmaceutical Association South Africa (IPASA)
Has been in the Pharmaceutical industry for 14 years, initially specializing in research and development and thereafter progressing into investment and now regulatory affairs. She previously worked for Mintek and Technology Innovation Agency (TIA). Currently, Judy is the Scientific and Regulatory Affairs Manager at IPASA. She is responsible for monitoring trends, issues, problems, opportunities and activities in the healthcare environment, with a specific focus on Scientific and Regulatory Affairs, in order to identify legislative issues that can affect the industry; developing IPASA positions on key issues in conjunction with members; and the overall coordination and support of a number of the IPASA Working Groups.
Dr Mbali Keele [PhD] – Moteli Consultants
Worked as a lecturer at the Department of Pharmacy of the Nelson Mandela Metropolitan University (NMMU) for eight years. More recently she was at the National Department of Health as a Medicines Research Officer within the Medicines Evaluation and Research (ME&R) Directorate, supporting the work of the Medicines Control Council. She rose to the rank of Acting Deputy Director of the Pre-registration Unit at the ME&R before leaving to join one of the largest pharmaceutical companies in South Africa within its Regulatory Affairs Unit. She has extensive knowledge in product formulation and medicine registration.
Dr Luther Gwaza [PhD] – Medicines Control Authority of Zimbabwe
Completed his Bachelor of Pharmacy (Honours) degree in 2005 and a Master of Philosophy (MPhil) in 2009 from the University of Zimbabwe. He completed his PhD in Pharmaceutical Policy and Regulatory in July 2016 at the Utrecht WHO Collaborating Centre for Pharmaceutical Policy and Regulation, which is based at the Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, the Netherlands.
Since 2007 Luther has been involved with the national drug regulatory authority (Medicines Control Authority of Zimbabwe) in Zimbabwe, and currently serve as a Consultant Regulatory Officer in the Evaluations and Registration Division. He has been involved in the World Health Organization Prequalification program since 2008. Over the last five years, Luther has been involved in various short- and long-term consulting assignments on medicines regulation in Africa and in Afghanistan. Currently he serves as a World Bank Consultant on the medicines regulatory harmonization project in the Southern African Development Community (SADC), a project under the African Medicines Regulatory Harmonization Initiative.